ArticleDiabetes care2023
Trends in the Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Commercially Insured Adults Aged <65 Years.
Article in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Diabetic retinopathy treatment cascade and care continuum in the USA: a systematic review.BMJ open · 2026Pooled it
- Current Trends in AI and Eye Disease Diagnostics.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Magnitude, patterns, and determinant factors of diabetic macular edema among people with diabetes at Debre Markos Referral Hospital, Northwest Ethiopia, 2025: a hospital-based cross-sectional study.International ophthalmology · 2026Article
- Long-term incidence and progression of vision-threatening diabetic retinopathy in Asian populations.Journal of global health · 2026Article
- Trends in prevalence and incidence of diabetic retinal disease in patients with type 1 and type 2 diabetes mellitus.Journal of diabetes and its complications · 2026Article
- Associations Between Initial Glycated Hemoglobin at Diabetes Diagnosis, Longitudinal Changes and Medication Effects, and the Severity and Progression of Sight-Threatening Diabetic Retinopathy.The Kaohsiung journal of medical sciences · 2026Article
- Real-world outcomes of anti-VEGF and corticosteroid therapies for diabetic macular edema: up to 10 years of follow-up in Korean patients.Japanese journal of ophthalmology · 2026Article
- Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy.International journal of molecular sciences · 2026Review
- Epidemiology and Associated Ocular Conditions of Visual Impairment in the United States: A Decade of Data from TriNetX US Network.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Continuing Medical Education as a Tool to Accelerate the Adoption of Extended-Duration Intravitreal Anti-VEGFs.Journal of CME · 2026Article
- Region-Specific Retinal and Choroidal Biomarkers Associated with Visual Outcomes After Anti-VEGF Treatment in Center-Involved Diabetic Macular Edema.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Clinical and optical coherence tomography predictors of spontaneous resolution of diabetic macular edema: incremental value of the subfoveal large choroidal vessel layer thickness ratio.Frontiers in medicine · 2026Article
- Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials.Ophthalmology and therapy · 2025Article
- Intravitreal anti-VEGF therapy and risk of limb complications in individuals with diabetic eye disease.Diabetes research and clinical practice · 2025Article
- Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US.Ophthalmology and therapy · 2025Article
- Twenty-Year Trends in Prevalence and Incidence of Diabetic Retinal Disease.Ophthalmology · 2025Article
- Unsupervised machine learning analysis of optical coherence tomography radiomics features for predicting treatment outcomes in diabetic macular edema.Scientific reports · 2025Article
- Plasma metabolomic profiling of diabetic macular edema.Scientific reports · 2025Article
- Assessment the real-world safety of intravitreal dexamethasone implant (Ozurdex): novel insights from a comprehensive pharmacovigilance analysis utilizing the FAERS database.BMC pharmacology & toxicology · 2025Article
- Practical Applications of Artificial Intelligence Diagnostic Systems in Fundus Retinal Disease Screening.International journal of general medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveExamine the 10-year trend in the prevalence and treatment of diabetic macular edema (DME) and vision-threatening diabetic retinopathy (VTDR) among commercially insured adults with diabetes. RESEARCH DESIGN AND
methodsWe analyzed the 10-year trend (2009-2018) in health care claims for adults aged 18-64 years using the IBM MarketScan Database, a national convenience sample of employer-sponsored health insurance. We included patients continuously enrolled in commercial fee-for-service health insurance for 24 months who had a diabetes ICD-9/10-CM code on one or more inpatient or two or more different-day outpatient claims in the index year or previous calendar year. We used diagnosis and procedure codes to calculate the annual prevalence of patients with one or more claims for 1) any DME, 2) either DME or VTDR, and 3) antivascular endothelial growth factor (anti-VEGF) injections and laser photocoagulation treatment, stratified by any DME, VTDR with DME, and VTDR without DME. We calculated the average annual percent change (AAPC).
resultsFrom 2009 to 2018, there was an increase in the annual prevalence of patients with DME or VTDR (2.1% to 3.4%; AAPC 7.5%; P < 0.001) and any DME (0.7% to 2.6%; AAPC 19.8%; P < 0.001). There were sex differences in the annual prevalence of DME or VTDR and any DME, with men having a higher prevalence than women. Annual claims for anti-VEGF injections increased among patients with any DME (327%) and VTDR with DME (206%); laser photocoagulation decreased among patients with any DME (-68%), VTDR with DME (-54%), and VTDR without DME (-62%).
conclusionsAnnual claims for DME or VTDR and anti-VEGF injections increased whereas those for laser photocoagulation decreased among commercially insured adults with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.